China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its JS213 sterile powder for injection. The drug is intended for use in combination with other anti-tumor drugs or as a standalone treatment for advanced malignant tumors.
JS213: Dual-Target Fusion Protein
JS213 is a fusion protein targeting both programmed-death 1 (PD-1) and interleukin-2 (IL-2). It is being developed to treat advanced malignant tumors and has demonstrated significant anti-tumor effects in multiple animal models during pre-clinical studies. Additionally, JS213 has shown a good and acceptable safety and tolerability profile, making it a promising candidate for further clinical development.
Global Clinical Development
Building on its pre-clinical success, JS213 has already entered Phase I trials abroad. The NMPA’s approval for clinical trials in China further expands the drug’s development pathway, bringing Junshi Biosciences closer to realizing its potential as a novel treatment option for patients with advanced malignant tumors.-Fineline Info & Tech
